Tigermed and Yingke PE led a USD100m Series C for Adlai Nortye, a China-based clinical-stage biopharmaceutical company focused on developing immuno-oncology medicines, with participation from ATCG Holdings, ICBC Asset Management, and two funds affiliated with Yingke PE. Read more